Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1.
about
Neurofibromin Loss of Function Drives Excessive Grooming in DrosophilaLTP-like plasticity in the visual system and in the motor system appear related in young and healthy subjectsTeaching reading to children with neurofibromatosis type 1: a clinical trial with random assignment to different approaches.Neurofibromatosis type 1 alternative splicing is a key regulator of Ras signaling in neuronsSpatial working memory in neurofibromatosis 1: Altered neural activity and functional connectivity.Understanding intellectual disability through RASopathies.Impairment of Procedural Learning and Motor Intracortical Inhibition in Neurofibromatosis Type 1 Patients.Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.Cognitive and behavioral problems in children with neurofibromatosis type 1: challenges and future directions.Impaired synaptic plasticity in RASopathies: a mini-review.Treatment of neurofibromatosis type 1.Brain and behaviour phenotyping of a mouse model of neurofibromatosis type-1: an MRI/DTI study on social cognition.Genetic disorders and neurobehavioural phenotypes.Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA).Genetic enhancement of Ras-ERK pathway does not aggravate L-DOPA-induced dyskinesia in mice but prevents the decrease induced by lovastatin
P2860
Q27347271-6AB66637-506D-4D46-89C5-FD0265CE51E8Q30401520-AE3DAD87-8DE1-4BC8-87BE-9CE75BCF82C9Q30670424-2B0EEB4D-96CC-46BF-B47E-135C311514A2Q33743618-6859A089-7F22-4847-AA95-F446D20816CDQ33885150-2755B288-EEAF-4A76-BFF9-A19E48656D61Q34558084-56F037F1-27BC-4B04-92F8-30148A837067Q36251932-07DA34A1-B80E-4235-918C-72BB3330DEA8Q36516773-E49424A3-EF4A-46D3-B6D0-009E084D6612Q36759465-6BA072C9-AD31-4299-97AB-6A1E1656D2CDQ37113976-61F32A56-E0BB-4990-BE6D-DF1C2F9646E2Q38243763-B7F5DB96-868D-4ED7-B720-E75D407C8015Q38937954-65CB60F2-7480-479D-B0DB-253ADAF4A3D0Q41008080-9F493684-FF5C-4031-83CE-57AD6F4015AEQ41721276-64052EF4-9CB7-45E6-AA50-07398E9CB4C8Q48143056-4E63A5CD-B7C2-4DC1-B678-5D580EE51CFEQ50301194-1A8455C2-8EB6-47E1-8444-BA12BCDF6577Q58603118-60AA441F-CC75-4AD0-B3CC-A7CC25353F75
P2860
Lovastatin improves impaired synaptic plasticity and phasic alertness in patients with neurofibromatosis type 1.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Lovastatin improves impaired s ...... with neurofibromatosis type 1.
@ast
Lovastatin improves impaired s ...... with neurofibromatosis type 1.
@en
Lovastatin improves impaired s ...... with neurofibromatosis type 1.
@nl
type
label
Lovastatin improves impaired s ...... with neurofibromatosis type 1.
@ast
Lovastatin improves impaired s ...... with neurofibromatosis type 1.
@en
Lovastatin improves impaired s ...... with neurofibromatosis type 1.
@nl
prefLabel
Lovastatin improves impaired s ...... with neurofibromatosis type 1.
@ast
Lovastatin improves impaired s ...... with neurofibromatosis type 1.
@en
Lovastatin improves impaired s ...... with neurofibromatosis type 1.
@nl
P2093
P2860
P356
P1433
P1476
Lovastatin improves impaired s ...... with neurofibromatosis type 1.
@en
P2093
Andreas Straube
Florian Heinen
Florian Mainberger
Karen Lidzba
Leonie Freudenberg
Martin Zenker
Nikolai H Jung
Sofia Granström
Steffen Berweck
Susanne Langer
P2860
P2888
P356
10.1186/1471-2377-13-131
P577
2013-10-02T00:00:00Z
P5875
P6179
1046448035